EIF4G1 Protein, Human (His-B2M-JD, Myc)

EIF4G1 is a key component of the eIF4F complex and plays a critical regulatory role in translation initiation. EIF4G1 plays different roles in complexes with EIF1 or EIF4E. EIF4G1 Protein, Human (His-B2M-JD, Myc) is the recombinant human-derived EIF4G1 protein, expressed by E.coli , with N-10*-B2M-JD and C- Myc labeled tag.

EIF4G1, a vital component of the eIF4F protein complex, plays a crucial role in the translation initiation process. Within the eIF4F complex, which recognizes the mRNA cap and facilitates mRNA recruitment to the ribosome, EIF4G1 exists in two mutually exclusive complexes, either with EIF1 or with EIF4E. When partnered with EIF1, EIF4G1 is essential for leaky scanning, particularly in avoiding cap-proximal start codons. Alternatively, when associated with EIF4E, EIF4G1 counteracts scanning promoted by EIF1-EIF4G1 and positions the start codon through a TISU element without scanning. As part of the eIF4F complex, EIF4G1 is required for endoplasmic reticulum stress-induced ATF4 mRNA translation. This multi-subunit eIF4F complex, with varying composition based on environmental conditions, includes EIF4A, EIF4E (cap-binding), and EIF4G1/EIF4G3. EIF4G1 interacts with the eIF3 complex, EIF4A1 or EIF4A2, EIF4E, and PABPC1. It interacts either with EIF4E or with EIF1 through a common binding site. Acting as a scaffold protein, EIF4G1 interacts with serine/threonine kinases MKNK1 and MKNK2 to facilitate EIF4E phosphorylation. Additionally, EIF4G1 engages in interactions with EIF4E3, CIRBP, MIF4GD, RBM4, HNRNPD/AUF1, DDX3X, and DAZAP2, highlighting its intricate involvement in translational regulation and mRNA circularization.

Human

E. coli

N-B2M;N-10*His;C-Myc

Q04637 (I1250-N1599)

1981

Partial

IEEYLHLNDMKEAVQCVQELASPSLLFIFVRHGVESTLERSAIAREHMGQLLHQLLCAGHLSTAQYYQGLYEILELAEDMEIDIPHVWLYLAELVTPILQEGGVPMGELFREITKPLRPLGKAASLLLEILGLLCKSMGPKKVGTLWREAGLSWKEFLPEGQDIGAFVAEQKVEYTLGEESEAPGQRALPSEELNRQLEKLLKEGSSNQRVFDWIEANLSEQQIVSNTLVRALMTAVCYSAIIFETPLRVDVAVLKARAKLLQKYLCDEQKELQALYALQALVVTLEQPPNLLRMFFDALYDEDVVKEDAFYSWESSKDPAEQQGKGVALKSVTAFFKWLREAEEESDHN

≥ 90%, as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.